TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Phase II Study Comparing Cabozantinib (NSC #761968) With Commercially Supplied Sunitinib in Patients With Previously Untreated Locally Advanced or Metastatic Renal Cell Carcinoma
Brief Summary: This randomized phase II trial studies how well cabozantinib-s-malate works compared to sunitinib malate in treating patients with previously untreated kidney cancer that has spread from where it started to nearby tissue or lymph nodes or to other places in the body. Cabozantinib-s-malate and sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether cabozantinib-s-malate is more effective than sunitinib malate in treating patients with kidney cancer.


Options:
A: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Cediranib Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Cediranib | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Cediranib Placebo; Assigned to Arm(s): 1
B: Arm Label: RAD001; Type: ACTIVE_COMPARATOR; Interventions: Drug: Everolimus | Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): RAD001 | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib
C: Arm Label: pazopanib followed by sunitinib; Type: EXPERIMENTAL; Interventions: Drug: pazopanib, Drug: sunitinib | Arm Label: sunitinib followed by pazopanib; Type: EXPERIMENTAL; Interventions: Drug: pazopanib, Drug: sunitinib | Intervention Type: DRUG; Name: pazopanib; Assigned to Arm(s): pazopanib followed by sunitinib, sunitinib followed by pazopanib | Intervention Type: DRUG; Name: sunitinib; Assigned to Arm(s): pazopanib followed by sunitinib, sunitinib followed by pazopanib
D: Arm Label: Arm I (cabozantinib-s-malate); Type: ACTIVE_COMPARATOR; Interventions: Drug: Cabozantinib S-malate, Other: Laboratory Biomarker Analysis | Arm Label: Arm II (sunitinib malate); Type: ACTIVE_COMPARATOR; Interventions: Other: Laboratory Biomarker Analysis, Drug: Sunitinib Malate | Intervention Type: DRUG; Name: Cabozantinib S-malate; Assigned to Arm(s): Arm I (cabozantinib-s-malate) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (cabozantinib-s-malate), Arm II (sunitinib malate) | Intervention Type: DRUG; Name: Sunitinib Malate; Assigned to Arm(s): Arm II (sunitinib malate)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Multicenter, Double-Blind, Placebo Controlled, Parallel Group Study of NT0102 in Children (Ages 6 12 Years) With Attention-Deficit Hyperactivity Disorder
Brief Summary: This is a randomized, double-blind, placebo-controlled, parallel group, Phase 3 trial to evaluate the safety and efficacy of NT0102 in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 12 years of age in a laboratory classroom study.


Options:
A: N/A
B: Arm Label: NT0102; Type: EXPERIMENTAL; Interventions: Drug: NT0102 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: NT0102; Assigned to Arm(s): NT0102 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Low Dose Methylphenidate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate | Arm Label: Medium Dose Methylphenidate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate | Arm Label: High Dose Methylphenidate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): Low Dose Methylphenidate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): Medium Dose Methylphenidate | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): High Dose Methylphenidate
D: Arm Label: Methylphenidate Transdermal System; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Transdermal System | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Concerta; Type: ACTIVE_COMPARATOR; Interventions: Drug: Concerta | Intervention Type: DRUG; Name: Methylphenidate Transdermal System; Assigned to Arm(s): Methylphenidate Transdermal System | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Concerta; Assigned to Arm(s): Concerta

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: iPad Technology for HOME Rehabilitation in Patients After Stroke: iHOME Acute/Chronic
Brief Summary: A pilot randomized, two parallel group study comparing an iPad software game application versus standard care in post-stroke patients.

Study hypothesis: Tablet PC technology using the iPad is a feasible and potentially efficacious tool which has the potential to promote fine motor recovery of the upper extremity after stroke.


Options:
A: Arm Label: Real prism glasses first, then sham; Type: EXPERIMENTAL; Interventions: Device: High power (57 prism diopter) peripheral prism glasses, Device: Low power sham peripheral prism glasses | Arm Label: Sham prism glasses first, then real; Type: EXPERIMENTAL; Interventions: Device: High power (57 prism diopter) peripheral prism glasses, Device: Low power sham peripheral prism glasses | Intervention Type: DEVICE; Name: High power (57 prism diopter) peripheral prism glasses; Assigned to Arm(s): Real prism glasses first, then sham, Sham prism glasses first, then real | Intervention Type: DEVICE; Name: Low power sham peripheral prism glasses; Assigned to Arm(s): Real prism glasses first, then sham, Sham prism glasses first, then real
B: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: HEP-OKS; Type: EXPERIMENTAL; Interventions: Behavioral: hemifield eye patching (HEP) + optokinetic stimulation (OKS) | Intervention Type: BEHAVIORAL; Name: hemifield eye patching (HEP) + optokinetic stimulation (OKS); Assigned to Arm(s): HEP-OKS
C: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Arm Label: Overground visual cue training; Type: EXPERIMENTAL; Interventions: Behavioral: Overground visual cue training | Arm Label: Treadmill visual cue training; Type: EXPERIMENTAL; Interventions: Behavioral: Treadmill visual cue training | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Usual Care | Intervention Type: BEHAVIORAL; Name: Overground visual cue training; Assigned to Arm(s): Overground visual cue training | Intervention Type: BEHAVIORAL; Name: Treadmill visual cue training; Assigned to Arm(s): Treadmill visual cue training
D: Arm Label: Standard/ Usual Care; Type: OTHER; Interventions: Other: Standard/ Usual Care | Arm Label: iPad Intervention; Type: EXPERIMENTAL; Interventions: Other: iPad Intervention | Intervention Type: OTHER; Name: iPad Intervention; Assigned to Arm(s): iPad Intervention | Intervention Type: OTHER; Name: Standard/ Usual Care; Assigned to Arm(s): Standard/ Usual Care

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Understanding Disparities in Quitting in African American and White Smokers
Brief Summary: The purpose of this study is to describe the differences in quitting smoking between African Americans (AA) and White smokers treated with varenicline.


Options:
A: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline tartrate (CP-526, 555-18) | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: varenicline tartrate (CP-526, 555-18); Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
B: Arm Label: African American (AA) Smokers; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: White Smokers; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): African American (AA) Smokers, White Smokers
C: Arm Label: Effectiveness of Nicotine patch only; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch | Arm Label: Effectiveness of Combination NRT; Type: EXPERIMENTAL; Interventions: Drug: Nicotine lozenge, Drug: Nicotine Patch | Arm Label: Effectiveness of Varenicline [Chantix]; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Effectiveness of Varenicline [Chantix] | Intervention Type: DRUG; Name: Nicotine lozenge; Assigned to Arm(s): Effectiveness of Combination NRT | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Effectiveness of Combination NRT, Effectiveness of Nicotine patch only
D: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Discharge Educational Strategies for Reduction of Vascular Events
Brief Summary: DESERVE is a discharge education study using health workers to enroll and randomly assign 800 subjects diagnosed with TIA, or mild stroke to either risk factor education or usual care. Those patients assigned to education will receive stroke preparedness education plus risk factor reduction education, and help accessing follow up care with health workers. Those patients assigned to usual care will receive written stroke preparedness education. This protocol will evaluate the effectiveness of this intervention to reduce blood pressure, and individual stroke risk factors and future stroke risk.


Options:
A: Arm Label: PREVENT program; Type: EXPERIMENTAL; Interventions: Behavioral: PREVENT program | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care | Intervention Type: BEHAVIORAL; Name: PREVENT program; Assigned to Arm(s): PREVENT program | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual Care
B: Arm Label: Stroke Survivors with CARE-CITE Carepartners; Type: EXPERIMENTAL; Interventions: Behavioral: Constraint-Induced Movement Therapy (CIMT) | Arm Label: CARE-CITE Education Program Carepartners; Type: EXPERIMENTAL; Interventions: Behavioral: CARE-CITE Education Program | Arm Label: Traditional Education Carepartners; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Traditional Education | Arm Label: Stroke Survivors with Traditional Education Carepartners; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Constraint-Induced Movement Therapy (CIMT) | Intervention Type: BEHAVIORAL; Name: CARE-CITE Education Program; Assigned to Arm(s): CARE-CITE Education Program Carepartners | Intervention Type: BEHAVIORAL; Name: Traditional Education; Assigned to Arm(s): Traditional Education Carepartners | Intervention Type: BEHAVIORAL; Name: Constraint-Induced Movement Therapy (CIMT); Assigned to Arm(s): Stroke Survivors with CARE-CITE Carepartners, Stroke Survivors with Traditional Education Carepartners
C: Arm Label: DESERVE education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DESERVE education | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: DESERVE education; Assigned to Arm(s): DESERVE education
D: Arm Label: Standard care (SC); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard care | Arm Label: Interventional care (IC); Type: EXPERIMENTAL; Interventions: Behavioral: CAPSYS | Intervention Type: BEHAVIORAL; Name: Standard care; Assigned to Arm(s): Standard care (SC) | Intervention Type: BEHAVIORAL; Name: CAPSYS; Assigned to Arm(s): Interventional care (IC)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Health Impact Evaluation of the "Community-Based Environmental Health Promotion Programme" in Rwanda
Brief Summary: Community Health Clubs to improve local sanitation, hygiene and health conditions have been implemented in several countries in Africa and Asia with some success. The Ministry of Health in Rwanda has committed to rolling out a program designed along similar lines, the Community Based Environmental Health Promotion Program (CBEHPP), in all 15000 villages across Rwanda. The main objective of the program is to achieve 'zero open defecation' in all villages of Rwanda, at least 80% hygienic latrine coverage and improvements in a range of health behaviors such as the use of mosquito nets, hand-washing with soap and the use of household water treatment.

To evaluate the impact of the program on health, other socio-economic outcomes and community functioning, a single district has been chosen where 150 communities will be randomized to receive the intervention immediately or 18 months later. The evaluation is led by US based Innovation for Poverty Action (IPA) through researchers based at the National University of Rwanda, Georgetown University, London School of Hygiene and Tropical Medicine and New York University. The research team will work in close collaboration with the implementing team, which consists of the Ministry of Health, Rwanda and Africa AHEAD.

The study will span three years, beginning in May 2013, and ending in late 2015.


Options:
A: Arm Label: Unconditional cash transfers; Type: EXPERIMENTAL; Interventions: Behavioral: Zomba Cash Transfer Program | Arm Label: Conditional Cash Transfer; Type: EXPERIMENTAL; Interventions: Behavioral: Zomba Cash Transfer Program | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Zomba Cash Transfer Program; Assigned to Arm(s): Conditional Cash Transfer, Unconditional cash transfers
B: Arm Label: Program participation; Type: EXPERIMENTAL; Interventions: Other: Enhanced-Homestead Food Production Program | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Enhanced-Homestead Food Production Program; Assigned to Arm(s): Program participation
C: Arm Label: Classic Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Classic Intervention | Arm Label: Minimum Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Minimum Intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Classic Intervention; Assigned to Arm(s): Classic Intervention | Intervention Type: BEHAVIORAL; Name: Minimum Intervention; Assigned to Arm(s): Minimum Intervention
D: Arm Label: Multi-sectoral agricultural intervention; Type: EXPERIMENTAL; Interventions: Other: Multi-sectoral agricultural intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Multi-sectoral agricultural intervention; Assigned to Arm(s): Multi-sectoral agricultural intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective Randomized Phase III Trial of Carboplatin/Gemcitabine/Bevacizumab vs. Carboplatin/Pegylated Liposomal Doxorubicin/Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer
Brief Summary: Evaluation of the best therapeutic index for patients with platinum-sensitive ovarian cancer when treatment with bevacizumab and gemcitabine/carboplatin or with bevacizumab and PLD/carboplatin.


Options:
A: Arm Label: Arm I (adjuvant chemotherapy suboptimally debulked); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Carboplatin, Procedure: Computed Tomography, Drug: Paclitaxel, Procedure: Therapeutic Conventional Surgery | Arm Label: Arm II (neoadjuvant chemotherapy); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Carboplatin, Procedure: Computed Tomography, Drug: Paclitaxel, Procedure: Therapeutic Conventional Surgery | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Arm I (adjuvant chemotherapy suboptimally debulked), Arm II (neoadjuvant chemotherapy) | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm I (adjuvant chemotherapy suboptimally debulked), Arm II (neoadjuvant chemotherapy) | Intervention Type: PROCEDURE; Name: Computed Tomography; Assigned to Arm(s): Arm I (adjuvant chemotherapy suboptimally debulked), Arm II (neoadjuvant chemotherapy) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm I (adjuvant chemotherapy suboptimally debulked), Arm II (neoadjuvant chemotherapy) | Intervention Type: PROCEDURE; Name: Therapeutic Conventional Surgery; Assigned to Arm(s): Arm I (adjuvant chemotherapy suboptimally debulked), Arm II (neoadjuvant chemotherapy)
B: Arm Label: Control Arm; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Research Arm; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: PLD, Biological: Bevacizumab | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Research Arm | Intervention Type: DRUG; Name: PLD; Assigned to Arm(s): Research Arm | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Research Arm
C: Arm Label: vargatef/Nintedanib; Type: EXPERIMENTAL; Interventions: Drug: vargatef | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: vargatef; Assigned to Arm(s): vargatef/Nintedanib | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: Arm I (cabozantinib-s-malate); Type: EXPERIMENTAL; Interventions: Drug: Cabozantinib S-malate, Other: Laboratory Biomarker Analysis | Arm Label: Arm II (paclitaxel); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Drug: Paclitaxel | Intervention Type: DRUG; Name: Cabozantinib S-malate; Assigned to Arm(s): Arm I (cabozantinib-s-malate) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (cabozantinib-s-malate), Arm II (paclitaxel) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm II (paclitaxel)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective Randomized Phase III Trial of Carboplatin/Gemcitabine/Bevacizumab vs. Carboplatin/Pegylated Liposomal Doxorubicin/Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer
Brief Summary: Evaluation of the best therapeutic index for patients with platinum-sensitive ovarian cancer when treatment with bevacizumab and gemcitabine/carboplatin or with bevacizumab and PLD/carboplatin.


Options:
A: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab, Drug: Placebo olaparib, Drug: Durvalumab placebo, Drug: Carboplatin+Paclitaxel | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Durvalumab, Drug: Placebo olaparib, Drug: Carboplatin+Paclitaxel | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Durvalumab, Drug: Olaparib, Drug: Carboplatin+Paclitaxel | Arm Label: tBRCAm cohort; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Durvalumab, Drug: Olaparib, Drug: Carboplatin+Paclitaxel | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Arm 1, Arm 2, Arm 3, tBRCAm cohort | Intervention Type: DRUG; Name: Durvalumab; Assigned to Arm(s): Arm 2, Arm 3, tBRCAm cohort | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Arm 3, tBRCAm cohort | Intervention Type: DRUG; Name: Placebo olaparib; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: DRUG; Name: Durvalumab placebo; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Carboplatin+Paclitaxel; Assigned to Arm(s): Arm 1, Arm 2, Arm 3, tBRCAm cohort
B: Arm Label: Experimental; Type: EXPERIMENTAL; Interventions: Drug: Sorafenib | Intervention Type: DRUG; Name: Sorafenib; Assigned to Arm(s): Experimental
C: Arm Label: Control Arm; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Research Arm; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: PLD, Biological: Bevacizumab | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Research Arm | Intervention Type: DRUG; Name: PLD; Assigned to Arm(s): Research Arm | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Research Arm
D: Arm Label: Niraparib monotherapy; Type: EXPERIMENTAL; Interventions: Drug: Niraparib | Arm Label: Niraparib-bevacizumab combination; Type: EXPERIMENTAL; Interventions: Drug: Niraparib, Drug: Bevacizumab | Intervention Type: DRUG; Name: Niraparib; Assigned to Arm(s): Niraparib monotherapy, Niraparib-bevacizumab combination | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Niraparib-bevacizumab combination

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Insulin Detemir Versus Insulin NPH: A Randomized Prospective Study Comparing Glycemic Control in Pregnant Women With Diabetes
Brief Summary: The aim of this study is to compare glycemic control in pregnant women treated with insulin Detemir and pregnant women treated with NPH insulin. These women are diagnosed with gestational diabetes (GDM) in the current pregnancy or have a preexisting diagnosis of type 2 diabetes (T2DM) at the onset of pregnancy. Our hypothesis is that there is no difference between these two treatment modalities in terms of glycemic control in diabetes.


Options:
A: Arm Label: Levemir; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin | Arm Label: NPH; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Levemir, NPH
B: Arm Label: Metformin; Type: EXPERIMENTAL; Interventions: Drug: Metformin | Arm Label: Insulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Insulin
C: Arm Label: Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: metformin | Arm Label: insulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: insulin | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: insulin; Assigned to Arm(s): insulin
D: Arm Label: Nutritional counseling & self blood glucose monitoring; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: nutritional counseling, Behavioral: self blood glucose monitoring | Arm Label: No treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: nutritional counseling; Assigned to Arm(s): Nutritional counseling & self blood glucose monitoring | Intervention Type: BEHAVIORAL; Name: self blood glucose monitoring; Assigned to Arm(s): Nutritional counseling & self blood glucose monitoring

Answer: A